Viatris to Acquire Pacira BioSciences for $1.65 Billion
Viatris has agreed to acquire all outstanding shares of Pacira BioSciences in a cash deal valued at $36.50 per share, totaling approximately $1.65 billion. The transaction is expected to close following regulatory approvals and other customary closing conditions. Pacira BioSciences specializes in innovative pain management products, including its Exparel platform for extended-release local anesthesia. Viatris aims to expand its portfolio by integrating Pacira’s offerings into its existing business lines. This acquisition aligns with Viatris’ strategy of strengthening its presence across key therapeutic areas through strategic acquisitions. The deal is anticipated to provide value to shareholders and enhance operational capabilities, potentially improving market positioning in the pharmaceutical sector.
Topics: acquisition pharmaceuticals